Tenosynovitis Drugs Global Market Report 2025

The tenosynovitis drugs market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the rise in sport injuries, the growing aging population, increased healthcare expenditure, greater awareness about tenosynovitis, and the increasing adoption of biologic treatments.

The tenosynovitis drugs market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to the expansion of telehealth services, global health initiatives, the rising prevalence of musculoskeletal disorders, growing demand for tenosynovitis drugs, and the increasing prevalence of chronic diseases. Key trends include advancements in surgical techniques, the integration of robotics in surgery, progress in minimally invasive procedures, innovations in nanotechnology, and developments in drug formulation.

The rising prevalence of musculoskeletal disorders is expected to significantly drive the growth of the tenosynovitis drugs market. Musculoskeletal disorders, which affect muscles, tendons, ligaments, nerves, and joints, cause pain and hinder movement. Factors such as aging populations, sedentary lifestyles, and increased occupational hazards contribute to the growing prevalence of these disorders. Tenosynovitis, a condition characterized by inflammation of the tendons and their sheaths, is treated with medications such as anti-inflammatory drugs and corticosteroids that reduce inflammation and alleviate pain. For example, in March 2023, the Office for Health Improvement and Disparities reported that 17.6% of individuals aged 16 and older in the UK had a long-term musculoskeletal condition, up from 17% in 2021. This increase in musculoskeletal conditions is contributing to the growing demand for tenosynovitis drugs.

The growing incidence of sports injuries is also fueling the demand for effective therapeutics in the tenosynovitis drugs market. Sports injuries, which can range from minor sprains to more severe fractures, often result from overuse, improper technique, or collisions during athletic activities. These injuries commonly involve tendon inflammation, and tenosynovitis drugs are used to treat them by reducing pain and swelling, thus facilitating faster recovery and improved mobility. For instance, a report by Howden Group Holdings Ltd. in November 2023 highlighted a significant surge in sports injuries in the English Premier League, including a 170% increase in ankle injuries, a 200% rise in calf/shin injuries, and a 130% increase in hamstring injuries following the FIFA World Cup Qatar 2022. The higher incidence of sports-related injuries is driving greater demand for tenosynovitis drugs.

Companies in the tenosynovitis drugs market are also innovating with advanced drug formulations to enhance treatment efficacy, minimize side effects, and improve patient adherence. For instance, in July 2024, ANI Pharmaceuticals Inc. received FDA approval for its Naproxen delayed-release tablets, which were introduced as a generic alternative to EC-Naprosyn. This formulation helps provide extended pain relief while reducing gastrointestinal irritation, making it an ideal treatment for inflammatory conditions such as tenosynovitis, tendonitis, and arthritis. These innovations in drug formulation are improving the overall treatment experience, which is expected to further drive market growth.

Major players in the tenosynovitis drugs market are Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, and AdvaCare Pharma.

North America was the largest region in the tenosynovitis drugs market in 2024. The regions covered in tenosynovitis drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tenosynovitis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tenosynovitis drugs are medications used to alleviate inflammation, pain, and swelling in the tendon sheath caused by conditions such as infection, overuse, or autoimmune diseases. Treatment options typically include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antibiotics for infectious cases. In severe or chronic inflammatory forms, disease-modifying antirheumatic drugs (DMARDs) or biologics may be prescribed.

The main drug types in the tenosynovitis drug market include NSAIDs, corticosteroids, antibiotics, and other medications. NSAIDs are commonly used to reduce pain and inflammation without steroids, helping manage tenosynovitis symptoms such as swelling and discomfort. These drugs are indicated for conditions such as De Quervain tenosynovitis, stenosing tenosynovitis, and trigger finger. They are available in various administration forms, including oral, injectable, and topical, and are distributed through hospital pharmacies, retail pharmacies, and online platforms.

The tenosynovitis drugs market research report is one of a series of new reports that provides tenosynovitis drugs market statistics, including the tenosynovitis drugs industry's global market size, regional shares, competitors with a tenosynovitis drugs market share, detailed tenosynovitis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tenosynovitis drugs industry. This tenosynovitis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tenosynovitis drugs market includes revenues earned by prescription medications, over-the-counter (OTC) products, biologics and disease-modifying drugs, topical treatments, injections, and infusions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.